Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage - A Gynecologic Oncology Group Study

Cancer

Volumn 77, Issue 6, 1996, Pages 1115-1121

  Zaino, Richard J ^a   Kurman, Robert J ^b   Diana, Karen L ^c   Morrow, C Paul ^d  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

adenocarcinoma; endometrium; female genitalia; neoplasms; pathology; risk

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CELL TYPE; ENDOMETRIUM CARCINOMA; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PERITONEAL FLUID; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; RISK FACTORS;

EID: 0029877968     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4     Document Type: Article

References (28)

1. Abeler V, Kjørdstad K, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992;2:9-22.
2. Eifel P, Ross J, Hendrickson M, Cox R, Kempson R, Martinez A. Adenocarcinoma of the endometrium: analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983;52:1026-31.
3. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(Suppl 8):2035-41.
4. Kadar N, Malfetano J, Homesley H. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: Implications for therapy. Obstet Gynecol 1992;80:655-9.
5. Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989;32(3): 288-91.
6. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. A Gynecologic Oncology Group Study. Gynecol Oncol 1991;40(1):55-65.
7. Zaino R, Kurman R, Herbold D, Gliedman J, Bundy BN, Voet R, et al. The significance of squamous differentiation in endometrial carcinoma. Cancer 1991;68:2293-02.
8. Larson E, Copeland L, Gallagher H, Kong JP, Wharton JT, Stringer CA. Prognostic factors in stage II endometrial carcinoma. Cancer 1987;60:1358-61.
9. Mirtal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups. Cancer 1988;61(3):538-45.
10. Tornos C, Silva EG, el-Naggar A, Burke TW. Aggressive stage I grade 1 endometrial carcinoma. Cancer 1992;70(4):790-8.
11. Fanning J, Alvarez P, Tsukada Y, MS P. Prognostic significance of the extent of cervical involvement by endometrial cancer. Gynecol Oncol 1991;40:46-7.
12. Soothill PW, Alcock CJ, Mac Kenzie IZ. Discrepancy between curettage and hysterectomy histology in patients with stage I uterine malignancy. Br J Obstet Gynecol 1989;96(4):478-81.
13. Cowles T, Javier F, Masterson B, Capen C. Comparison of clinical and surgical staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66:413-6.
14. Chen S. Extrauterine spread in endometrial carcinoma clinically confined to the uterus. Gynecol Oncol 1985;21:23-31.
15. Grimshaw R, Tupper W, Fraser R, Tomkins M, Jeffrey J, Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol 1990;36:97-100.
16. Kadar N, Homesley H, Malfetano J. Positive peritoneal cytology is an adverse risk factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992;46:145-9.
17. Geisinger K, Homesley H, Morgan T, Kute T, Marshall R. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986;58:1518-25.
18. Britton L, Wilson T, Gaffey T, Lieber M, Wieand H, Podratz K. Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 1989;34:317-22.
19. Kadar N, Malfetano J, Homesley H. Steroid receptor concentrations in endometrial carcinoma; effect on survival in surgically staged patients. Gynecol Oncol 1993;50:281-6.
20. Carcangiu M, Chambers J, Voynick I, Pirro M, Schwartz P. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 1990;94:255-60.
21. FIGO stages-1988 revision. Gynecol Oncol 1989;35:125-126.
22. Gusberg S. The problem of staging endometrial cancer. Obstet Gynecol 1966;28:305-8.
23. Zaino RJ, Silverberg SF, Morris HJ, Bundy BN, Morrow CP, Okagaki T. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 1993;13:29-36.
24. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Amer Stat Assoc 1958;53:457-81.
26. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; B 34:187-202.
27. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991; 67(12):3093-103.
28. Lukes A, Kohler M, Pieper C, Kerns BJ, Bentley R, Rodrigues GC, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.